ASH 2024: Eli Lilly to highlight Jaypirca® data and promising BAFF-RxCD3 antibody research for B-Cell malignancies
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, will be presented at the 66th American Society of… read more.
